Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview
Table of Contents
Executive Summary
Chapter 1: Age-Related Macular Degeneration
Wet AMD
Dry AMD
Chapter 2: Therapeutic Efficacy
Anti-VEGF therapies
Pegaptanib
Bevacizumab
Ranibizumab
VEGF Trap-EYE
Chapter 3: Oraya Therapeutics
Radiotherapy platform
Automatic Positioning System (APS)
I-Guide
System software
Radiation dosing
Potential complications and risk factors
Competitive advantage
Challenges and areas of improvement
Future expectations
Interview with Jim Taylor
Radiation therapy
Competitive advantage
Challenges encountered
Areas of improvement
Future expectations
Chapter 4: VisionCare Ophthalmic Technologies
Company background
Telescope technology
Complications and challenges
Interview with Reena Mishra
Company background
Telescope technology
Competitive advantage
Complications and challenges
Chapter 5: Omeros
Company background
PharmacoSurgery platform
Pipeline
Competitive advantage
Challenges encountered
Validation
Future expectations
Interview with Greg Demopulos
Company background
PharmacoSurgery platform
OMS302
Competitive advantage
Challenges encountered
Validation procedure
Future expectations
Chapter 6: Kala Pharmaceuticals
Company background
Mucosal penetrating products (MPP)
Competitive advantage
Future endeavors
Interview with Kim Brazzell
Company background
Mucosal penetrating products (MPP)
Challenges encountered
Competitive advantage
Future endeavor
Chapter 7: Platforms and Products
Chapter 8: Survey of Ocular Industry
Areas of development
Promising targets and therapies
Challenges encountered
Chapter 9: Clinical Trials and Pipeline Data
Chapter 10
Company Profiles 79
13therapeutics, Inc. 79
2C Tech Corporation, Inc. 79
AbbVie Inc. 80
Abdi Ìbrahim Ìlac Sanayi ve Tic A.S. (Abdi Ibrahim) 80
AC Immune SA 80
ACADIA Pharmaceuticals 80
Aciex Therapeutics, Inc. 81
Aciont Inc. 81
Acorn Biomedical, Inc. 81
Actavis hf. 82
Acucela Inc. 82
Adamed Sp. z o.o. 82
Adenovir Pharma AB 83
AdeTherapeutics Inc. 83
Aerie Pharmaceuticals, Inc. 83
Aerpio Therapeutics, Inc. 84
Akebia Therapeutics, Inc. 84
Akorn Pharmaceuticals, Inc. 84
Alcon Laboratories, Inc. 85
Alexion Pharmaceuticals, Inc. Translational Medicine Center 85
Alimera Sciences, Inc. 85
Alkeus Pharmaceuticals, Inc. 86
Allegro Ophthalmics LLC 86
Allergan, Inc. 86
Allergan S.A.U. 87
Altacor 87
Altheos, Inc. 87
Amakem Therapeutics NV 88
AmorChem L.P. 88
AngioLab, Inc. 88
Ångstrom Pharmaceuticals, Inc. 89
Apellis Pharmaceuticals, Inc. 89
Apitope International NV 89
Applied Genetic Technologies Corp. (AGTC) 90
ArcticDx, Inc. 90
Argos Therapeutics, Inc. 90
AriBio 91
Ascendis Pharma A/S 91
AsclepiX Therapeutics, LLC 91
Asklepios BioPharmaceutical, Inc. 92
Aspireo Pharmaceuticals Limited 92
Aus Bio Limited 92
Auven Therapeutics Management L.L.L.P. 93
Avalanche Biotechnologies, Inc. 93
Avedro 93
Axxam S.p.A. 94
Bach Pharma, Inc. 94
Bausch & Lomb 94
Bausch & Lomb Canada Inc. 95
Bayer Yakuhin, Ltd. 95
BCN Peptides S.A. 95
Beijing Northland Biotech Co., Ltd. 96
Beijing Tide Pharmaceutical Co., Ltd. 96
Benitec Biopharma Ltd. 96
Betastem Therapeutics, Inc. 97
Bicycle Therapeutics Limited 97
Binex Co., Ltd. 97
Biocodex S.A. 98
Biocycive 98
BioDiem Ltd 98
Bioftalmik 99
BioMotiv LLC 99
Bionure 99
Biophytis 100
Bloomage BioTechnology Corporation Limited 100
BluBio (Yantai) Biopharmaceutical Co., Ltd. 100
Bohus BioTech AB 101
Boston Children’s Hospital 101
Brill Pharma 101
Calista Therapeutics, Inc. 102
Can-Fite BioPharma Ltd. 102
Catalyst Biosciences 102
Cell Cure Neurosciences Ltd 103
CellSeed Inc. 103
Celsus Therapeutics plc 103
Celtaxsys, Inc. 103
Charlesson LLC 104
Chia Tai Tianquing Pharmaceutical Group Co., Ltd 104
China Resources Zizhu Pharmaceutical Co., Ltd 104
Circadian Technologies Limited 105
Clayton Biotechnologies, Inc. 105
Clearside Biomedical, Inc. 105
Compugen Ltd. 106
Corena Therapeutics SARL 106
D.Western Therapeutics Institute, Inc. 107
Dalian Innobioactives Co., Ltd. 107
Diaxonhit Therapeutics 107
DIOPTIC Laboratories, Inc. 107
DNAVEC Corporation 108
Dompé s.p.a. 108
Dong-A ST 108
Eleven Biotherapeutics, Inc. 109
Eli Lilly and Company 109
Emcure Pharmaceuticals Ltd. 109
Encore Vision, Inc. 109
Envisia Therapeutics™, Inc. 110
Enzo Biochem, Inc. 110
Eos Neuroscience, Inc. 110
EryDel S.p.A. 111
ESBATech, a Novartis company 111
Essex Bio-Technology Limited 111
Esteve 111
Eupraxia Pharmaceuticals Inc. 112
Europharm Laboratoires Co. Ltd. 112
Evonik Corporation 112
Exonate 113
EyeGate Pharmaceuticals, Inc. 113
EyeGene, Inc. 113
EyeTechCare SA 113
Eye Therapies LLC 114
Eyevensys SA 114
F. Hoffmann-La Roche AG 114
Farmaprojects S.A.U. 115
Farmigea S.p.A. 115
FirstString Research, Inc. 115
Foamix Pharmaceuticals Ltd. 115
Fondazione Telethon 116
ForSight Labs, LLC 116
ForSight VISION5, Inc. 116
Freedom Meditech, Inc. 117
La Fundación General de la Universidad de Valladolid FGUVa 117
Galecto Biotech AB 117
Genable Technologies Ltd. 117
Genentech, Inc. 118
Gene Signal International SA 118
GenSight Biologics 118
Genzyme® Corporation 119
GlaxoSmithKline plc 119
GrayBug® LLC 119
Griffin Discoveries BV 120
G-treeBNT Co., Ltd. 120
HanAll BioPharma Co. Ltd. 120
Hanlim Pharmaceuticals Inc. 120
Harmonic Pharma 121
Healios KK 121
Hemera Biosciences, Inc. 121
Herantis Pharma plc 122
High Point Pharmaceuticals, LLC (formerly TransTech Pharma, Inc.) 122
Horus Pharma 122
Hubei Kangzheng Pharmaceutical Co., Ltd. 122
Hyundai Pharm. Ind. Co., Ltd. 123
iCo Therapeutics Inc. 123
Iconic Therapeutics, Inc. 123
Ilsung Pharmaceuticals Co. Ltd. 124
Imagen Biotech, Inc. 124
Immco Diagnostics, Inc. 124
Immunservice GmbH 124
Implandata Ophthalmic Products GmbH 125
Imprimis Pharmaceuticals, Inc. 125
Inflamalps SA 125
InFlectis BioScience 126
InnoCore Technologies BV 126
InnoPharma, Inc. 126
Innovent Biologics, Inc. 127
Inotek Pharmaceuticals Corporation 127
InSite Vision Incorporated 128
Intellect Neurosciences, Inc. 128
InteRNA Technologies B.V. 128
International Stem Cell Corporation 128
Intrexon Corporation 129
ipal GmbH 129
Isis Pharmaceuticals, Inc. 129
iSTAR Medical SA 130
Jade Therapeutics, Inc. 130
Jiangsu Farever Pharmaceutical Co., Ltd. 130
Jiangsu T-mab BioPharma 130
Kala Pharmaceuticals, Inc. 131
KalVista Pharmaceuticals Ltd. 131
Kangmei Pharmaceutical Co., Ltd. 131
Korea Research Institute of Chemical Technology 132
Kowa Company, Ltd. 132
Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. 132
Kytogenics Pharmaceuticals, Inc. 132
Laboratoires Genévrier 133
Laboratoires Théa 133
Laboratorios SALVAT S.A. 133
Laboratorios Sophia S.A. de C.V. 133
Lacerta Bio Inc. 133
LambdaVision, Inc. 134
Lee’s Pharmaceutical Holdings Ltd. 134
Lexicon Pharmaceuticals, Inc. 134
Livwel Therapeutics, Inc. 135
Lotus Innovative Health, Ltd. 135
Lpath Incorporated 135
MacuCLEAR, Inc. 135
MacuLogix, Inc. 136
Mati Therapeutics, Inc. 136
Merck Serono (EMD Serono) 136
Mesoblast Limited 137
Meta-IQ 137
Mimetogen Pharmaceuticals, Inc. 137
Mitsubishi Tanabe Pharma Corporation 137
Molecular Partners AG 138
Montefarmaco OTC S.p.A. 138
Moorfields Pharmaceuticals 138
Mystic Pharmaceuticals 138
Myungmoon Pharm. Co., Ltd. 139
Nanomerics 139
Nano Retina, Inc. 139
NanoVector srl 140
NanoViricides, Inc. 140
Nektar Therapeutics 140
NEMUS Bioscience, Inc. 140
Neothetics™, Inc. 141
Neuroptis Biotech 141
Neuroscienze PharmaNess S.c.a.r.L. 141
Neurotech Pharmaceuticals, Inc. 141
Nexus Pharamaceuticals, Inc. 142
NicOx Research Institute SRL 142
NicOx S.A. 142
NightstaRx Ltd. 142
NovaBay Pharmaceuticals, Inc. 143
Novaliq GmbH 143
NovaMedica LLC 143
Novartis International AG 144
Novartis Ophthalmics AG 144
NovelMed Therapeutics, Inc. 144
Ocata Therapeutics, Inc. 145
Ocugen, Inc. 145
Oculeve 145
Oculis ehf 146
Ogenx Therapeutics Corporation, Inc. 146
Ohr Pharmaceutical Inc. 146
Omeros Corporation 146
OMIDA AG 147
ONL Therapeutics LLC 147
OphthaliX, Inc. 147
OphthalmoPharma Ltd. 147
Ophthotech Corp. 148
Opocrin S.p.A. 148
Opthea Pty Ltd 148
Ora Bio Ltd. 149
Oraya Therapeutics, Inc. 149
Otsuka Pharmaceutical Europe Ltd 149
Oxford BioMedica plc 149
OxiGENE, Inc. 150
Palobiofarma S.L 150
Panoptes Pharma GmbH 150
PanOptica, Inc. 150
Parion Sciences 151
PDL BioPharma, Inc. 151
Perrigo Company plc 151
Pfenex Inc. 152
Pfizer 152
Pharma Two B Ltd. 153
Physica Pharma 153
Pieris Pharmaceuticals, Inc. 153
Pierre Fabre SA 154
PIQUR Therapeutics AG 154
Pixium Vision SA 154
PolyActiva Pty Ltd. 155
Potentia Pharmaceuticals, Inc. 155
Present Value Ltd 155
Promedior, Inc. 155
ProRetina Therapeutics, S.L. 156
Provectus Biopharmaceuticals, Inc. 156
pSivida Corp. 156
QLT Inc 157
Quark Pharmaceuticals, Inc. 157
Rapid Pathogen Screening, Inc. 157
Reata Pharmaceuticals, Inc. 158
Regeneron Pharmaceuticals 158
RegeneRx Biopharmaceuticals, Inc. 158
REGENXBIO Inc. 159
ReNeuron Group plc 159
Resolvyx Pharmaceuticals, Inc. 159
RestorGenex Corporation 160
RetroSense Therapeutics LLC 160
Rigel Pharmaceuticals, Inc. 160
River Vision Development Corp. 161
Roche Diagnostics GmbH 161
Roche SAS 161
R-Tech Ueno, Ltd. 161
RXi Pharmaceuticals Corporation 161
Sam Chun Dang Pharm. Co., Ltd 162
Samil Pharm. Co., Ltd. 162
SanBio, Inc. 162
Sanitas AB 162
Sanofi S.A. 163
Santen Pharmaceutical Co., Ltd. 163
Santhera Pharmaceuticals 163
SATT Lutech 164
SCYNEXIS, Inc. 164
Senju Pharmaceutical Co., Ltd 164
Shire plc 165
SIFI SpA 165
Silvanols 165
Sirnaomics, Inc. 166
SK Biopharmaceuticals 166
Solx, Inc. 166
Spark Therapeutics, Inc. 167
Specialised Therapeutics Australia Pty Ltd 167
Starpharma 167
Stealth Peptides International (Shanghai) Inc. 168
Stelic Institute & Co., Inc. 168
Stelis Biopharma Pvt. Ltd. 168
StemCells, Inc. 169
Strathclyde University, Health Technologies 169
Streuli Pharma AG 169
Strides Arcolab Ltd. 169
Sucampo Pharmaceuticals, Inc. 170
Sun Pharma Advanced Research Company (SPARC) Ltd. 170
Suzhou Sirnaomics Biopharmaceuticals Co. Ltd. 170
Sylentis S.A. 170
SynCore Biotechnology Co., Ltd 170
Synovo GmbH 171
Tacere Therapeutics, Inc. 171
Tactical Therapeutics, Inc. 171
Taejoon Pharm Co., Ltd. 172
Taiwan Liposome Company Ltd. 172
TearScience®, Inc. 172
Teijin Pharma Limited 172
ThromboGenics NV 173
TLC Biopharmaceuticals B.V. 173
TOA EIYO LTD. 173
TopiVert Ltd. 173
TRACON Pharmaceuticals, Inc. 174
TRB Chemedica International S.A. 174
TxCell 174
UNIMED PHARMA, spol. s r.o. 175
UNITHER Pharmaceuticals 175
University of Nottingham 175
University of Santiago de Compostela 175
Valeant Pharmaceuticals International, Inc. 176
Valentia Biopharma S.L. 176
Venture Life Ltd 176
Vibalogics GmbH 177
VisionCare Ophthalmic Technologies. Inc. 177
VISIOTACT Pharma 177
Wellstat Ophthalmics Corporation 177
X-BODY Biosciences, Inc. 178
Xcovery Vision 178
Xediton Pharmaceuticals Inc. 178
XOMA Corporation 179
Youcare Pharmaceutical Group Co., Ltd. 179
ZeaVision®, LLC 179
Ziarco 179
References
List of Tables
Table 2.1: Clinical status for common therapies for wet AMD
Table 3.1 Platform specifications
Table 4.1: Platform specifications
Table 5.1: Targets and their clinical status
Figure 6.1: Targets and their clinical status
Table 7.1: Targets in clinical stages
Table 7.2: Therapeutic platform specifications
List of Figures
Figure 8.1: Areas of research
Figure 8.2: Ocular disorders of interest
Figure 8.3: Promising therapies for ocular diseases
Figure 8.4: Promising targets for ocular therapies
Figure 8.5: Challenges encountered
Global Artificial Tears Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 91
Artificial tears are lubricant eye drops used to treat The dryness and irritation associated with deficient tear production in keratoconjunctivitis sicca (dry eyes). They are also used to moisten contact lenses and in eye examinations.
The global Artificial Tears market was valued at US$ 2921.6 million in 2023 and is anticipated to reach US$ 5240.1 million by 2030, witnessing a CAGR of 8.6% during The forecast period 2024-2030.
The industry's leading producers are Aller......
Global Contact Lens Solution Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 96
Contact lens solution is a kind of solution that is used to contact lens with The function of cleaning, disinfection, rinsing or preservation, it can also alleviate The eyeball discomfort which caused by wear The contact lens. Contact lens solution can direct contact eyeball, so it must be accord with industrial standard.
The global Contact Lens Solution market was valued at US$ 4087.6 million in 2023 and is anticipated to reach US$ 5323.5 million by 2030, witnessing a CAGR of 3.8% ......
Global Latanoprost Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 82
Latanoprost drops is a clear colorless liquid and a medication used to treat increased pressure inside The eye. Onset of effects is usually within four hours, and they last for up to a day.
Latanoprost is used to treat high pressure inside The eye due to glaucoma (open angle type) or other eye diseases (e.g., ocular hypertension). It is similar to a natural chemical in The body (prostaglandin) and works by regulating The flow of fluid within The eye which results in lower pressure. Lowerin......
Global Contact Lens Solution Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 99
Market Overview of Global Contact Lens Solution market:
According to our latest research, the global Contact Lens Solution market looks promising in the next 5 years. As of 2022, the global Contact Lens Solution market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Contact ......
Global Dry Eye Syndrome Drugs Market Research Report 2024
Published: 04-Jan-2024 Price: US 2900 Onwards Pages: 82
The Dry Eye Syndrome Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dry Eye Syndrome Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive......
Global Eye Drops & Lubricants Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 112
According to our LPI (LP Information) latest study, the global Eye Drops & Lubricants market size was valued at US$ 8841.8 million in 2023. With growing demand in downstream market, the Eye Drops & Lubricants is forecast to a readjusted size of US$ 9780.8 million by 2030 with a CAGR of 1.5% during review period.
The research report highlights the growth potential of the global Eye Drops & Lubricants market. Eye Drops & Lubricants are expected to show stable growth in the future market. H......
Global Conjunctivitis Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 98
According to our LPI (LP Information) latest study, the global Conjunctivitis market size was valued at US$ 3482.7 million in 2023. With growing demand in downstream market, the Conjunctivitis is forecast to a readjusted size of US$ 3908 million by 2030 with a CAGR of 1.7% during review period.
The research report highlights the growth potential of the global Conjunctivitis market. Conjunctivitis are expected to show stable growth in the future market. However, product differentiation, r......
Global Contact Lens Solution Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 118
According to our LPI (LP Information) latest study, the global Contact Lens Solution market size was valued at US$ 3998.7 million in 2023. With growing demand in downstream market, the Contact Lens Solution is forecast to a readjusted size of US$ 5241.5 million by 2030 with a CAGR of 3.9% during review period.
The research report highlights the growth potential of the global Contact Lens Solution market. Contact Lens Solution are expected to show stable growth in the future market. Howev......
Global Latanoprost Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 90
According to our LPI (LP Information) latest study, the global Latanoprost market size was valued at US$ 1344.2 million in 2023. With growing demand in downstream market, the Latanoprost is forecast to a readjusted size of US$ 1574.2 million by 2030 with a CAGR of 2.3% during review period.
The research report highlights the growth potential of the global Latanoprost market. Latanoprost are expected to show stable growth in the future market. However, product differentiation, reducing co......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
